文献速递慢阻肺

RIPK1激酶依赖性炎症与细胞死亡参与慢阻肺发病机制

RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD.
PubMed 文献 · Eur Respir J · 2023-04-01

研究基于人及小鼠肺单细胞RNA测序、COPD患者肺组织免疫组化,以及Ripk1 S25D/S25D激酶缺陷小鼠和RIPK1抑制剂GSK'547的动物实验,发现COPD中RIPK1表达升高,遗传或药理抑制RIPK1激酶活性可减轻香烟暴露及弹性蛋白酶诱导的气道炎症、重塑、肺气肿和细胞死亡,提示RIPK1激酶抑制可能成为COPD新治疗策略。

要点

  • COPD患者气道上皮RIPK1蛋白水平显著高于从不吸烟者及无气流受限吸烟者。
  • 遗传或药理抑制RIPK1激酶活性可减轻香烟暴露小鼠的气道炎症、重塑和肺气肿。
  • RIPK1激酶抑制或为COPD新型治疗方向,尚需临床验证。

核心结论

  • RIPK1激酶抑制在COPD实验模型中具有保护作用,可能代表一种新的有前景的治疗方法。

研究设计与样本

  • 评估人和小鼠肺单细胞RNA测序数据中RIPK1表达,并通过免疫组化验证COPD患者肺组织RIPK1水平。
  • 使用Ripk1 S25D/S25D激酶缺陷小鼠和RIPK1激酶抑制剂GSK'547,在实验性COPD中评估遗传和药理抑制RIPK1激酶活性的后果。

主要发现

  • 人COPD中RIPK1表达在肺泡1型(AT1)、AT2、纤毛和神经内分泌细胞中增加。
  • COPD患者气道上皮RIPK1蛋白水平较从不吸烟者和无气流受限吸烟者显著增加。
  • 小鼠香烟烟雾(CS)暴露使AT2细胞中Ripk1表达类似增加,并在肺泡巨噬细胞和T细胞中进一步增加。
  • 遗传和/或药理抑制RIPK1激酶活性显著减轻急性及亚急性CS暴露后的气道炎症,以及慢性CS暴露后的气道重塑、肺气肿和凋亡与坏死性凋亡细胞死亡。
  • 药理抑制RIPK1激酶显著减轻弹性蛋白酶诱导的肺气肿和肺功能下降;CS暴露小鼠肺组织RNA-seq显示药理抑制RIPK1激酶后细胞死亡和炎症通路下调。

关键数值与推荐

  • RIPK1蛋白水平在COPD患者气道上皮中较从不吸烟者和无气流受限吸烟者显著增加。
  • 遗传和/或药理抑制RIPK1激酶活性显著减轻急性及亚急性CS暴露后的气道炎症。
  • 慢性CS暴露下抑制RIPK1激酶活性显著减轻气道重塑、肺气肿及凋亡和坏死性凋亡细胞死亡。
  • 药理抑制RIPK1激酶显著减轻弹性蛋白酶诱导的肺气肿和肺功能下降。

临床怎么用

  • RIPK1激酶抑制可能作为COPD的潜在新型治疗策略,目前证据来自实验模型,尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of regulated cell death (including apoptosis and necroptosis) and inflammation, both drivers of COPD pathogenesis. We aimed to define the contribution of RIPK1 kinase-dependent cell death and inflammation in the pathogenesis of COPD. METHODS: We assessed RIPK1 expression in single-cell RNA sequencing (RNA-seq) data from human and mouse lungs, and validated RIPK1 levels in lung tissue of COPD patients via immunohistochemistry. Next, we assessed the consequences of genetic and pharmacological inhibition of RIPK1 kinase activity in experimental COPD, using Ripk1 S25D/S25D kinase-deficient mice and the RIPK1 kinase inhibitor GSK'547. RESULTS: RIPK1 expression increased in alveolar type 1 (AT1), AT2, ciliated and neuroendocrine cells in human COPD. RIPK1 protein levels were significantly increased in airway epithelium of COPD patients compared with never-smokers and smokers without airflow limitation. In mice, exposure to cigarette smoke (CS) increased Ripk1 expression similarly in AT2 cells, and further in alveolar macrophages and T-cells. Genetic and/or pharmacological inhibition of RIPK1 kinase activity significantly attenuated airway inflammation upon acute and subacute CS exposure, as well as airway remodelling, emphysema, and apoptotic and necroptotic cell death upon chronic CS exposure. Similarly, pharmacological RIPK1 kinase inhibition significantly attenuated elastase-induced emphysema and lung function decline. Finally, RNA-seq on lung tissue of CS-exposed mice revealed downregulation of cell death and inflammatory pathways upon pharmacological RIPK1 kinase inhibition. CONCLUSIONS: RIPK1 kinase inhibition is protective in experimental models of COPD and may represent a novel promising therapeutic approach.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Van Eeckhoutte HP, Donovan C, Kim RY, et al. RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD. Eur Respir J. 2023. PMID: 36549711. doi:10.1183/13993003.01506-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。